SCHEMBL2905967

SCHEMBL2905967

C=C[C@H]1CC[C@H]2[C@@H]3CC(=O)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 13/20 0.62
CYP17A1 P05093 3/20 0.49
CYP3A4 P08684 4/20 0.47
LMNA P02545 4/20 0.46
HSD17B10 Q99714 3/20 0.46
TSHR P16473 3/20 0.46
NR3C1 P04150 2/20 0.46
SHBG P04278 2/20 0.46
PGR P06401 2/20 0.46
SERPINA6 P08185 2/20 0.46
AR P10275 2/20 0.46
SNCA P37840 2/20 0.46
CACNA1C Q13936 2/20 0.46
CYP51A1 Q16850 2/20 0.46
GPBAR1 Q8TDU6 2/20 0.46
SIGMAR1 Q99720 2/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
OR51E2 Q9H255 1/20 0.46
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7884266 0.83 CYP19A1 (0.68) CYP19A1CYP3A4LMNAHSD17B10TSHR
SCHEMBL7520546 0.83 CYP19A1 (0.68) CYP19A1CYP3A4LMNAHSD17B10TSHR
SCHEMBL3648448 0.82 LMNA (0.69) CYP19A1CYP17A1CYP3A4LMNAHSD17B10
SCHEMBL13917679 0.82 LMNA (0.69) CYP19A1CYP17A1CYP3A4LMNAHSD17B10
SCHEMBL7886505 0.82 CYP17A1 (0.59) CYP19A1CYP17A1CYP3A4LMNAHSD17B10
SCHEMBL7886509 0.82 CYP17A1 (0.59) CYP19A1CYP17A1CYP3A4LMNAHSD17B10
SCHEMBL11754338 0.82 CYP3A4 (0.69) CYP19A1CYP3A4LMNAHSD17B10TSHR
SCHEMBL11754343 0.82 CYP3A4 (0.69) CYP19A1CYP3A4LMNAHSD17B10TSHR
SCHEMBL2600423 0.82 CYP3A4 (0.69) CYP19A1CYP3A4LMNAHSD17B10TSHR
SCHEMBL6899636 0.81 CYP3A4 (0.74) CYP19A1CYP17A1CYP3A4LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240245788-A1 LIPID PRODRUGS OF NEUROSTEROIDS PURETECH LYT, INC. (US) 2024-07-25 US disclosed
US-11975073-B2 Lipid prodrugs of neurosteroids PURETECH LYT, INC. (US) 2024-05-07 US disclosed
US-20230338552-A1 LIPID PRODRUGS OF NEUROSTEROIDS PURETECH LYT, INC. (US) 2023-10-26 US disclosed
US-20230338552-A1 LIPID PRODRUGS OF NEUROSTEROIDS PURETECH LYT, INC. (US) 2023-10-26 US disclosed
US-20230338552-A1 LIPID PRODRUGS OF NEUROSTEROIDS PURETECH LYT, INC. (US) 2023-10-26 US disclosed
US-20220395513-A1 LIPID PRODRUGS OF NEUROSTEROIDS PURETECH LYT, INC. (US) 2022-12-15 US disclosed
US-20220395513-A1 LIPID PRODRUGS OF NEUROSTEROIDS PURETECH LYT, INC. (US) 2022-12-15 US disclosed
EP-4100017-A1 LIPID PRODRUGS OF NEUROSTEROIDS PureTech LYT, Inc. (US) 2022-12-14 EP disclosed
CN-115348864-A Lipid prodrugs of neurosteroids 纯技术LYT股份有限公司 2022-11-15 CN disclosed
WO-2021159021-A1 LIPID PRODRUGS OF NEUROSTEROIDS PURETECH LYT, INC. (US) 2021-08-12 WO disclosed
US-6066627-A ALTERING BLOOD CONCNETRATION OF LUTEINIZING HORMONE PHERIN CORPORATION (US) 2000-05-23 US disclosed
US-6057439-A EPOXYSTEROIDS PHERIN CORPORATION (US) 2000-05-02 US disclosed
US-5994333-A NASAL ADMINISTERING PHERIN CORPORATION (US) 1999-11-30 US disclosed
EP-0891188-A1 STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH Pherin Pharmaceuticals, Inc. (US) 1999-01-20 EP disclosed
WO-1998014194-A9 STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF ANXIETY 1998-08-27 WO disclosed
WO-1998003207-A9 STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF PMS AND ANXIETY 1998-05-22 WO disclosed
WO-1998014194-A1 STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF ANXIETY PHERIN PHARMACEUTICALS (US) 1998-04-09 WO disclosed
WO-1997036596-A9 STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH 1997-12-04 WO disclosed
WO-1997036596-A1 STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH PHERIN PHARMACEUTICALS, INC. (US) 1997-10-09 WO disclosed
US-5563131-A Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods PHERIN CORPORATION (US) 1996-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230338552-A1 LIPID PRODRUGS OF NEUROSTEROIDS CYP21A2, CYP46A1, CYP17A1 CYP19A1 10/4885CYP17A1 3/4885CYP3A4 175/4885
US-20240245788-A1 LIPID PRODRUGS OF NEUROSTEROIDS CYP21A2, CYP46A1, CYP17A1 CYP19A1 10/4885CYP17A1 3/4885CYP3A4 175/4885
US-20220395513-A1 LIPID PRODRUGS OF NEUROSTEROIDS CYP21A2, CYP46A1, CYP17A1 CYP19A1 10/4885CYP17A1 3/4885CYP3A4 175/4885
US-11975073-B2 Lipid prodrugs of neurosteroids CYP21A2, CYP46A1, CYP17A1 CYP19A1 10/4885CYP17A1 3/4885CYP3A4 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.